BIOMAT Database Logo BIOMAT Database Logo

Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11. 1990

M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
Cancer Research Campaign Laboratories, University of Nottingham, University Park, UK.

Serum from patients with systemic breast cancer was found to contain elevated levels of polymorphic epithelial mucin (PEM) as detected using an immunoradiometric assay employing the monoclonal antibody NCRC-11. PEM was partially purified from pooled sera from these patients and the complex, polymorphic, high-molecular-mass (greater than 400 kDa) mucin was identified by sodium dodecylsulphate/polyacrylamide gel electrophoresis, Western blotting and immunostaining with the NCRC-11 antibody. Serial serum samples from 16 patients with metastatic breast cancer were assayed for circulating PEM defined by the monoclonal antibody NCRC-11. The clinical course of disease in these patients was assessed independently as progressive, static or responsive. Increasing NCRC-11 antigen levels correlated with disease progression in 6/7 patients, and decreasing antigen levels correlated with an objective response to treatment in 5/6 patients. Measurement of NCRC-11-defined PEM antigen in patients undergoing therapy for metastatic breast cancer showed an overall accuracy of 75%.

UI MeSH Term Description Entries
D009077 Mucins High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface. Mucin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015592 Immunoradiometric Assay Form of radioimmunoassay in which excess specific labeled antibody is added directly to the test antigen being measured. Assay, Immunoradiometric,Assays, Immunoradiometric,Immunoradiometric Assays

Related Publications

M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
September 1987, British journal of cancer,
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
Monoclonal antibody NCRC 11 reactivity with advanced breast carcinoma: lack of prognostic value.
December 1988, Histopathology,
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.
March 1985, British medical journal (Clinical research ed.),
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization.
May 1984, Histopathology,
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
Epitope analysis of monoclonal antibody NCRC-11 defined antigen isolated from human ovarian and breast carcinomas.
September 1986, British journal of cancer,
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
Biochemical and immunochemical analysis of a breast carcinoma associated antigen defined by the monoclonal antibody NCRC-11.
January 1987, Archiv fur Geschwulstforschung,
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
Detection of mammary serum antigen in sera from breast cancer patients using monoclonal antibody 3E1.2.
December 1988, Cancer research,
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer.
July 1991, British journal of cancer,
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
NCRC-11 immunoperoxidase staining patterns in breast cancer: interpretive and technical reproducibility.
November 1987, Histopathology,
M R Price, and A J Clarke, and J F Robertson, and C O'Sullivan, and R W Baldwin, and R W Blamey
Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7.
January 2001, The Journal of rheumatology,
Copied contents to your clipboard!